% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Papadimitriou:169665,
author = {N. Papadimitriou and M. J. Gunter and N. Murphy and A.
Gicquiau and D. Achaintre and S. Brezina and T. Gumpenberger
and A. Baierl and J. Ose and A. J. Geijsen and E. H. van
Roekel and A. Gsur and B. Gigic and N. Habermann$^*$ and C.
M. Ulrich and E. Kampman and M. P. Weijenberg and P.-M.
Ueland and R. Kaaks$^*$ and V. Katzke$^*$ and V. Krogh and
B. Bueno-de-Mesquita and E. Ardanaz and R. C. Travis and M.
B. Schulze and M.-J. Sánchez and S. M. Colorado-Yohar and
E. Weiderpass and A. Scalbert and P. Keski-Rahkonen},
title = {{C}irculating tryptophan metabolites and risk of colon
cancer: results from case-control and prospective cohort
studies.},
journal = {International journal of cancer},
volume = {149},
number = {9},
issn = {1097-0215},
address = {Bognor Regis},
publisher = {Wiley-Liss},
reportid = {DKFZ-2021-01487},
pages = {1659-1669},
year = {2021},
note = {2021 Nov 1;149(9):1659-1669},
abstract = {Dysregulation of tryptophan metabolism has been linked to
colorectal tumorigenesis, however, epidemiological studies
investigating tryptophan metabolites in relation to
colorectal cancer risk are limited. We studied associations
of plasma tryptophan, serotonin, and kynurenine with colon
cancer risk in two studies with cancer patients and
controls, and in one prospective cohort: ColoCare Study (110
patients/153 controls), the Colorectal Cancer Study of
Austria (CORSA; 46 patients/390 controls), and the European
Prospective Investigation into Cancer and Nutrition (EPIC;
456 matched case-control pairs). Logistic regression was
used to estimate odds ratios (OR) and $95\%$ confidence
intervals (CI) for colon cancer risk. Tryptophan was
inversely associated with colon cancer risk in ColoCare [OR
per 1-standard deviation (SD) = 0.44; $95\%$ CI, 0.31-0.64]
and EPIC (OR per 1-SD = 0.86; $95\%$ CI, 0.74-0.99).
Comparing detectable versus non-detectable levels, serotonin
was positively associated with colon cancer in CORSA
(OR = 6.39; $95\%$ CI, 3.61-11.3) and EPIC (OR = 2.03;
$95\%$ CI, 1.20-3.40). Kynurenine was inversely associated
with colon cancer in ColoCare (OR per 1-SD = 0.74; $95\%$
CI, 0.55-0.98), positively associated in CORSA (OR per
1-SD = 1.79; $95\%$ CI, 1.27-2.52), while no association
was observed in EPIC. The kynurenine-to-tryptophan ratio was
positively associated with colon cancer in ColoCare (OR per
1-SD = 1.38; $95\%$ CI, 1.03-1.84) and CORSA (OR per
1-SD = 1.44; $95\%$ CI, 1.06-1.96), but not in EPIC. These
results suggest that higher plasma tryptophan may be
associated with lower colon cancer risk, while increased
serotonin may be associated with a higher risk of colon
cancer. The kynurenine-to-tryptophan ratio may also reflect
altered tryptophan catabolism during colon cancer
development. This article is protected by copyright. All
rights reserved.},
keywords = {Tryptophan (Other) / colon cancer (Other) / kynurenine
(Other) / plasma (Other) / serotonin (Other)},
cin = {C120 / C020},
ddc = {610},
cid = {I:(DE-He78)C120-20160331 / I:(DE-He78)C020-20160331},
pnm = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
pid = {G:(DE-HGF)POF4-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:34196970},
doi = {10.1002/ijc.33725},
url = {https://inrepo02.dkfz.de/record/169665},
}